vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and AdvanSix Inc. (ASIX). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -0.8%, a 11.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 3.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
ANIP vs ASIX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $359.9M |
| Net Profit | $27.5M | $-2.8M |
| Gross Margin | — | 7.6% |
| Operating Margin | 14.1% | -0.7% |
| Net Margin | 11.1% | -0.8% |
| Revenue YoY | 29.6% | 9.4% |
| Net Profit YoY | 367.5% | -892.9% |
| EPS (diluted) | $1.14 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $359.9M | ||
| Q3 25 | $227.8M | $374.5M | ||
| Q2 25 | $211.4M | $410.0M | ||
| Q1 25 | $197.1M | $377.8M | ||
| Q4 24 | $190.6M | $329.1M | ||
| Q3 24 | $148.3M | $398.2M | ||
| Q2 24 | $138.0M | $453.5M | ||
| Q1 24 | $137.4M | $336.8M |
| Q4 25 | $27.5M | $-2.8M | ||
| Q3 25 | $26.6M | $-2.6M | ||
| Q2 25 | $8.5M | $31.4M | ||
| Q1 25 | $15.7M | $23.3M | ||
| Q4 24 | $-10.3M | $352.0K | ||
| Q3 24 | $-24.2M | $22.3M | ||
| Q2 24 | $-2.3M | $38.9M | ||
| Q1 24 | $18.2M | $-17.4M |
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 17.9% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | 14.1% | -0.7% | ||
| Q3 25 | 15.9% | -0.9% | ||
| Q2 25 | 6.6% | 7.7% | ||
| Q1 25 | 13.3% | 7.7% | ||
| Q4 24 | -2.3% | -3.9% | ||
| Q3 24 | -13.8% | 7.5% | ||
| Q2 24 | 3.7% | 11.5% | ||
| Q1 24 | 14.8% | -7.0% |
| Q4 25 | 11.1% | -0.8% | ||
| Q3 25 | 11.7% | -0.7% | ||
| Q2 25 | 4.0% | 7.7% | ||
| Q1 25 | 8.0% | 6.2% | ||
| Q4 24 | -5.4% | 0.1% | ||
| Q3 24 | -16.3% | 5.6% | ||
| Q2 24 | -1.7% | 8.6% | ||
| Q1 24 | 13.2% | -5.2% |
| Q4 25 | $1.14 | $-0.11 | ||
| Q3 25 | $1.13 | $-0.10 | ||
| Q2 25 | $0.36 | $1.15 | ||
| Q1 25 | $0.69 | $0.86 | ||
| Q4 24 | $-0.45 | $0.02 | ||
| Q3 24 | $-1.27 | $0.82 | ||
| Q2 24 | $-0.14 | $1.43 | ||
| Q1 24 | $0.82 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $19.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $815.2M |
| Total Assets | $1.4B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $19.8M | ||
| Q3 25 | $262.6M | $23.7M | ||
| Q2 25 | $217.8M | $18.4M | ||
| Q1 25 | $149.8M | $8.3M | ||
| Q4 24 | $144.9M | $19.6M | ||
| Q3 24 | $145.0M | $17.3M | ||
| Q2 24 | $240.1M | $12.1M | ||
| Q1 24 | $228.6M | $20.6M |
| Q4 25 | $540.7M | $815.2M | ||
| Q3 25 | $505.8M | $818.2M | ||
| Q2 25 | $436.8M | $823.7M | ||
| Q1 25 | $418.6M | $794.4M | ||
| Q4 24 | $403.7M | $774.6M | ||
| Q3 24 | $405.9M | $766.4M | ||
| Q2 24 | $455.8M | $746.6M | ||
| Q1 24 | $452.0M | $713.2M |
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $63.7M |
| Free Cash FlowOCF − Capex | $29.1M | $36.1M |
| FCF MarginFCF / Revenue | 11.8% | 10.0% |
| Capex IntensityCapex / Revenue | 0.5% | 7.7% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $6.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $63.7M | ||
| Q3 25 | $44.1M | $26.6M | ||
| Q2 25 | $75.8M | $21.1M | ||
| Q1 25 | $35.0M | $11.4M | ||
| Q4 24 | $15.9M | $64.2M | ||
| Q3 24 | $12.5M | $57.3M | ||
| Q2 24 | $17.4M | $50.2M | ||
| Q1 24 | $18.3M | $-36.2M |
| Q4 25 | $29.1M | $36.1M | ||
| Q3 25 | $38.0M | $66.0K | ||
| Q2 25 | $71.8M | $-7.2M | ||
| Q1 25 | $32.5M | $-22.6M | ||
| Q4 24 | $13.5M | $29.8M | ||
| Q3 24 | $7.7M | $26.8M | ||
| Q2 24 | $13.0M | $16.7M | ||
| Q1 24 | $13.7M | $-71.6M |
| Q4 25 | 11.8% | 10.0% | ||
| Q3 25 | 16.7% | 0.0% | ||
| Q2 25 | 34.0% | -1.7% | ||
| Q1 25 | 16.5% | -6.0% | ||
| Q4 24 | 7.1% | 9.1% | ||
| Q3 24 | 5.2% | 6.7% | ||
| Q2 24 | 9.4% | 3.7% | ||
| Q1 24 | 10.0% | -21.3% |
| Q4 25 | 0.5% | 7.7% | ||
| Q3 25 | 2.7% | 7.1% | ||
| Q2 25 | 1.9% | 6.9% | ||
| Q1 25 | 1.3% | 9.0% | ||
| Q4 24 | 1.3% | 10.4% | ||
| Q3 24 | 3.2% | 7.7% | ||
| Q2 24 | 3.2% | 7.4% | ||
| Q1 24 | 3.3% | 10.5% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 0.67× | ||
| Q1 25 | 2.23× | 0.49× | ||
| Q4 24 | — | 182.29× | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
